Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.

Niu G, Chen X.

Curr Drug Targets. 2010 Aug;11(8):1000-17. Review.

2.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
3.

Vascular endothelial growth factor: biology and therapeutic applications.

Ho QT, Kuo CJ.

Int J Biochem Cell Biol. 2007;39(7-8):1349-57. Epub 2007 Apr 22. Review.

4.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
5.

Radiolabeled small molecule inhibitors of VEGFR - recent advances.

Kniess T.

Curr Pharm Des. 2012;18(20):2867-74. Review.

PMID:
22571655
6.

Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.

Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y, D'Onofrio A.

Drug Discov Today. 2011 Dec;16(23-24):1052-60. doi: 10.1016/j.drudis.2011.08.007. Epub 2011 Aug 22. Review.

PMID:
21875682
7.

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Hicklin DJ, Ellis LM.

J Clin Oncol. 2005 Feb 10;23(5):1011-27. Epub 2004 Dec 7. Review.

PMID:
15585754
8.
9.

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.

Gacche RN, Meshram RJ.

Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24139944
10.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
11.

[The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].

Grépin R, Pagès G.

J Soc Biol. 2009;203(2):181-92. doi: 10.1051/jbio/2009022. Epub 2009 Jun 16. Review. French.

PMID:
19527632
12.

Tumor angiogenesis and anti-angiogenic therapy.

Kubota Y.

Keio J Med. 2012;61(2):47-56. Review.

13.

Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

Sitohy B, Nagy JA, Dvorak HF.

Cancer Res. 2012 Apr 15;72(8):1909-14. doi: 10.1158/0008-5472.CAN-11-3406. Review.

14.

Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.

Leite de Oliveira R, Hamm A, Mazzone M.

Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Review.

PMID:
21540050
15.

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.

Drug Discov Today. 2011 Mar;16(5-6):219-28. doi: 10.1016/j.drudis.2011.01.005. Epub 2011 Jan 22. Review.

PMID:
21262381
16.

Vascular endothelial growth factor (VEGF) inhibition--a critical review.

Moreira IS, Fernandes PA, Ramos MJ.

Anticancer Agents Med Chem. 2007 Mar;7(2):223-45. Review.

PMID:
17348829
17.

Assessing the in vivo efficacy of biologic antiangiogenic therapies.

Wilson PM, LaBonte MJ, Lenz HJ.

Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9. Review.

PMID:
23053262
18.

Anti-angiogenic alternatives to VEGF blockade.

Khan KA, Bicknell R.

Clin Exp Metastasis. 2016 Feb;33(2):197-210. doi: 10.1007/s10585-015-9769-3. Epub 2015 Nov 30. Review.

19.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

20.

Supplemental Content

Support Center